GLP-1 drugs for obesity: what TikTok gets right and wrong

What did @mrdoctoroficial__ actually say?

Honestly, this one is hard to fact-check in the traditional sense. The transcript is largely incoherent, a mix of garbled Spanish and English that doesn't produce a clear, quotable medical claim. The creator references something called "Pundayo" from Eli Lilly, describes it as being "in pill form," and suggests it's doing serious work in weight loss. The hashtag category points squarely at GLP-1 receptor agonists, and the caption asks whether a pill can fight obesity.

The most identifiable claim seems to be that Eli Lilly has a GLP-1 medication in oral form that is producing meaningful results. If that's the intended message, there's actually something worth examining here, because that claim isn't baseless. But the delivery is so muddled that viewers are left to guess what the actual point is, which is a problem for health content reaching 10,000 people.

Does the science back this up?

There is legitimate science behind an oral GLP-1 option from Eli Lilly, specifically orforglipron, a small-molecule GLP-1 receptor agonist that doesn't require injection. Early trial data is real and moderately promising.

A phase 2 trial published in the New England Journal of Medicine (Rosenstock et al., 2023) showed orforglipron produced weight loss of up to 14.7% over 36 weeks in adults with obesity, without the need for injection. That's a meaningful result. Eli Lilly is also developing another oral candidate. These are not approved drugs yet. They are in clinical development, and phase 3 data is still being gathered. The FDA has not approved any oral GLP-1 agonist for weight management as of early 2025. Calling this a "pill against obesity" available now is premature. The science is encouraging. The product is not on shelves.

What did they get wrong (or right)?

Credit where it's due: the general direction of the claim, that an oral GLP-1 from Eli Lilly exists and is showing results, is grounded in real clinical activity. That's more than a lot of TikTok health content gives you.

What's wrong, or at least sloppy: the framing implies this is a current treatment option. It isn't. Orforglipron has not received FDA approval for obesity treatment. Presenting pipeline drugs as if they're ready for patients is a recurring problem in health content, and it causes real harm. People ask their doctors for things that don't exist yet, or turn to unregulated sources when their doctor says no. The word "Pundayo" doesn't correspond to any approved or announced drug name in Lilly's portfolio, which raises questions about accuracy or translation errors in the transcript. The lack of any safety discussion is also a significant gap. GLP-1 receptor agonists carry real side effects, including nausea, pancreatitis risk, and potential thyroid concerns flagged in animal studies.

What should you actually know?

Oral GLP-1 receptor agonists are a real area of active development, and the early data is worth watching. But "worth watching" and "ready to take" are very different things.

Currently, the only FDA-approved oral GLP-1 option for any indication is semaglutide tablets (Rybelsus), approved for type 2 diabetes, not weight loss. Wegovy and Zepbound, the approved weight-loss GLP-1 options, are injections. Orforglipron and similar small-molecule candidates from Lilly and others are still in trials. If and when they reach approval, they will go through a full regulatory review process. In the meantime, compounded versions of GLP-1 drugs circulating online are not equivalent to FDA-approved brand-name medications, and the FDA has issued warnings about compounded semaglutide products. If you're interested in GLP-1 therapy for weight management, talk to a licensed clinician who can assess whether you're a candidate, explain the actual approved options, and monitor you properly.